Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aurinia Pharm Ord (NQ: AUPH )

5.160 +0.060 (+1.18%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,336,019
Open 5.120
Bid (Size) 5.030 (15)
Ask (Size) 5.160 (5)
Prev. Close 5.100
Today's Range 5.040 - 5.180
52wk Range 4.710 - 12.43
Shares Outstanding 128,395,927
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AUPH Stock Earnings: Aurinia Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
AUPH stock results show that Aurinia Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire

Performance

YTD
-40.96%
-40.96%
1 Month
+2.18%
+2.18%
3 Month
-31.66%
-31.66%
6 Month
-37.76%
-37.76%
1 Year
-53.89%
-53.89%

More News

Read More
Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
From Aurinia Pharmaceuticals Inc.
Via Business Wire
The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Earnings Scheduled For February 15, 2024
Via Benzinga
Earnings Outlook For Aurinia Pharmaceuticals
Via Benzinga
UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia to Participate in Upcoming Investor Healthcare Conferences
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Aurinia Pharmaceuticals Finds No Buyer After Strategic Business Review, Launches Stock Buyback
Via Benzinga
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Why Herbalife Shares Are Trading Lower By Around 36%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire
What's Going On With Aurinia Pharmaceuticals Stock?
Via Benzinga
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Submits IND Application to US Food & Drug Administration for AUR 200
From Aurinia Pharmaceuticals Inc.
Via Business Wire
What's Going On With Aurinia Pharmaceuticals Stock?
Via Benzinga
Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
This Oil Giant Is 'Not Great, Not Bad,' But Jim Cramer Says 'I'm Sticking With My Coterra'
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.